secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telesis Bio Inc. (—)
CIK:        0001850079
Form:       8-K
Filed at:   2023-08-29T23:59:59+00:00
Accession:  0001193125-23-223802
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Telesis Bio appoints William Kullback as CFO effective August 28, 2023
----------------------------------------------------------------------

- Kullback's base salary set at $430,000 with target bonus of 50% of salary and $100,000 signing bonus.
- Company will recommend a grant of an option to purchase 300,000 shares of common stock.
- Previously CFO at BioLegend, where he led its $5.25B sale to Revvity (PerkinElmer).
- Kullback also served as CFO at Lombard Medical (Nasdaq: EVAR) from 2014 to 2017.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850079/000119312523223802/0001193125-23-223802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850079/000119312523223802/d333931d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-223802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer